Novo Nordisk takes beating after slashing full-year growth


Save Story
Leer en español

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

COPENHAGEN, Denmark (AP) — Danish drug maker Novo Nordisk says it has lowered its long-term guidance for 2016 due to a difficult U.S. market, sparking a nearly 14 percent drop in share prices in early Friday trading in Copenhagen.

The group says the U.S. market environment "has become significantly more challenging" adding it "no longer deems it achievable" to reach the operating profit growth target of 10 percent, lowering it to 5 percent.

Novo Nordisk, one of the world's leading makers of diabetes medicines, reported a 3-percent increase in sales and a 17-percent profit increase in the third quarter.

Last month, it announced plans to lay off some 1,000 employees globally to reduce operating costs mainly because of the U.S. markets.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

Business
The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast